Regeneron’s earnings report drops tomorrow, and Wall Street is buzzing—last quarter they smashed expectations with $3.61 billion in revenue, a 19% surge, and surprise EPS. Analysts now expect a modest 3.8% revenue bump, which aligns with last year’s performance, and Regeneron’s track record suggests they’re likely to hit it. Meanwhile, rival Incyte crushed it with a 37.7% sales jump, and the biotech sector is on fire, up 4.4% in the past month—with Regeneron’s stock soaring over 10%. Analysts are pricing in a $819 average target, way above current levels. All signs point to strong momentum—watch this space.
Listen in comfort: Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN: advertise@thednn.ai
This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai.
Podden och tillhörande omslagsbild på den här sidan tillhör
The Daily News Now!. Innehållet i podden är skapat av The Daily News Now! och inte av,
eller tillsammans med, Poddtoppen.
